Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | RUSNANO Takes a Medical Track: Investment in Manufacturing Drugs in Organic NanopacksA project to produce a number of pharmaceuticals recently won approval from the Supervisory Council of RUSNANO. The total budget for the project is 831 million rubles.
By: Rusnano press-service A project to produce a number of pharmaceuticals— As a result of implementing the project, in 2010–2015 a Russian company will establish original commercial production of medications that are without parallel in the entire world. The unique technology for fusing the most dissimilar drug substances in phospholipid nanoparticles was developed in the Russian Federation. It will enable the project company to enter the market with innovative and highly effective forms of medications in only one to two years, with minimal risk, and with a minimal budget. The capsules of drug nanoparticles (micelles) are composed of phospholipids— The scientific investigator, the body responsible for conducting experimental work and medical trials for the project, will be the V.N. Orekhovich Institute of Biomedical Chemistry of the Russian Academy of Medical Sciences. Its chief, Academic Alexander Archakov, is one of the world’s leading specialists in medical nanobiotechnology. Project company EkhoBiPharmDubna, located in the special economic zone in Dubna, Moscow Oblast, will produce the nanomedications. “Drug production and supplies to the drug delivery system is an innovative area of the pharmaceutical industry worldwide,” noted Academic Archakov. “The scientific group in this project has already made particularly valuable contribution to phospholipid- The first series of drugs are expected to enter production and sale in 2011–2012. These will be nanoforms of indometacin (a non-steroid anti-inflammatory drug), prednisolone (a steroid anti-inflammatory drug), and chlorine-E6 (an active ingredient in photosensitizers— RUSNANO Managing Director Olga Shpichko commented: “Drugs produced with this technology are going to be highly competitive in the marketplace because of the originality and universality of the know-how. The modest price of nanomedications and their considerably greater effectiveness than traditional counterparts will make the new drugs available to a huge portion of the populace. Therefore, this project has tremendous social importance.” Russian Corporation of Nanotechnologies (RUSNANO) was established in 2007 with the major strategic goal of fostering the development of innovative processes in the field of nanotechnologies through their commercialization. It aims to do this by acting as a co-investor in nanotechnology projects likely to make a significant economic or social impact. Creating the innovative environment, RUSNANO helps to develop nanotech infrastructure and supports education of industry professionals. To assist the Russian nanotech industry to strengthen its international links and advance to the global market, RUSNANO develops partnerships with the world’s leading nanotechnology centers and organizes the annual Nanotechnology International Forum in Russia. The management bodies of RUSNANO are the Supervisory Council, the Executive Board, and the Chief Executive Officer. In September 2008 Anatoly Chubais was appointed CEO of the Russian Corporation of Nanotechnologies. By January 2010 the Supervisory Council of the corporation has approved financing of 61 projects with total funding of 192.8 bln rubles of which RUSNANO will finance 91 bln rubles. To learn more about RUSNANO and/or to submit your project for investment consideration please visit our website www.rusnano.com # # # RUSNANO, established in 2007, fosters innovative processes in the field of nanotechnologies through their commercialization in Russia. RUSNANO helps to develop infrastructure and supports education. End
Account Email Address Disclaimer Report Abuse
|
|